A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Merck

ClinicalTrials.gov Identifier:

NCT00730275

First received: August 6, 2008

Last updated: December 21, 2011

Last verified: December 2011

History of Changes

Results First Received: December 21, 2011

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Type 2 Diabetes
Interventions:	Drug: Sitagliptin phosphate Drug: Comparator: matching placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Sitagliptin 50 mg	Participants who received a single oral dose of sitagliptin 50 mg.
Sitagliptin 100 mg	Participants who received a single oral dose of sitagliptin 100 mg.
Sitagliptin 200 mg	Participants who received a single oral dose of sitagliptin 200 mg.
Placebo	Participants who received a single oral dose of a matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.

Participant Flow: Overall Study

	Sitagliptin 50 mg	Sitagliptin 100 mg	Sitagliptin 200 mg	Placebo
STARTED	9	9	8	9
COMPLETED	9	9	8	8
NOT COMPLETED	0	0	0	1
Withdrawal by Subject	0	0	0	1

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Sitagliptin 50 mg	Participants who received a single oral dose of sitagliptin 50 mg.
Sitagliptin 100 mg	Participants who received a single oral dose of sitagliptin 100 mg.
Sitagliptin 200 mg	Participants who received a single oral dose of sitagliptin 200 mg.
Placebo	Participants who received a single oral dose of a matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
Total	Total of all reporting groups

Baseline Measures

	Sitagliptin 50 mg	Sitagliptin 100 mg	Sitagliptin 200 mg	Placebo	Total
Number of Participants [units: participants]	9	9	8	9	35
Age [units: years] Mean ± Standard Deviation	13.9 ± 2.52	14.3 ± 1.41	14.8 ± 1.75	14.1 ± 2.26	14.3 ± 1.98
Gender [units: participants]
Female	6	5	5	8	24
Male	3	4	3	1	11

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Participants Who Experienced at Least One Adverse Event [ Time Frame: Pre-study through 10 to 14 days following administration of study drug ]

Show Outcome Measure 1

2. Primary:

Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin [ Time Frame: Pre-dose through 72 hours post-dose ]

Show Outcome Measure 2

3. Secondary:

Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin [ Time Frame: Pre-dose through 72 hours post-dose ]

Show Outcome Measure 3

4. Secondary:

Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin [ Time Frame: Pre-dose through 72 hours post-dose ]

Show Outcome Measure 4

5. Secondary:

Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin [ Time Frame: Pre-dose through 72 hours post-dose ]

Hide Outcome Measure 5

Measure Type	Secondary
Measure Title	Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin
Measure Description	Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.
Time Frame	Pre-dose through 72 hours post-dose
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.

Reporting Groups

	Description
Sitagliptin 50 mg	Participants who received a single oral dose of sitagliptin 50 mg.
Sitagliptin 100 mg	Participants who received a single oral dose of sitagliptin 100 mg.
Sitagliptin 200 mg	Participants who received a single oral dose of sitagliptin 200 mg.

Measured Values

	Sitagliptin 50 mg	Sitagliptin 100 mg	Sitagliptin 200 mg
Number of Participants Analyzed [units: participants]	9	9	8
Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin [units: hours] Mean ± Standard Deviation	12.1 ± 1.7	11.2 ± 2.1	11.7 ± 1.8

No statistical analysis provided for Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin

6. Secondary:

Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo [ Time Frame: Pre-dose through 24 hours post-dose ]

Show Outcome Measure 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Vice President, Late Stage Development Group Leader
Organization: Merck Sharpe & Dohme Corp
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com

No publications provided

Responsible Party:	Merck
ClinicalTrials.gov Identifier:	NCT00730275 History of Changes
Other Study ID Numbers:	MK-0431-081, 2008_540
Study First Received:	August 6, 2008
Results First Received:	December 21, 2011
Last Updated:	December 21, 2011
Health Authority:	United States: Food and Drug Administration

To Top